Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 117, Issue 3, Pages 620-622Publisher
BLACKWELL PUBLISHING LTD
DOI: 10.1046/j.1365-2141.2002.03499.x
Keywords
chronic myeloid leukaemia; skin; Stevens-Johnson syndrome; STI571; tyrosine kinase inhibitor
Categories
Ask authors/readers for more resources
Between seven and 21% of patients treated with the specific tyrosine kinase inhibitor STI571 have been reported to develop mild-to-moderate severity of adverse cutaneous reactions. We report a patient in the blast crisis phase of chronic myeloid leukaemia who developed a life-threatening cutaneous reaction, Stevens-Johnson syndrome, following 1 week of STI571 therapy. This report may serve to remind the clinician about the possible severe cutaneous side-effects of STI571 before instituting more extensive clinical application of this agent in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available